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A New Oral Therapy for Long QT Syndrome
Long-Term Oral Potassium Improves
Repolarization in Patients With HERG Mutations
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OBJECTIVES We sought to determine whether oral potassium supplementation safely increases serum K
and results in sustained improvement of repolarization parameters in long QT syndrome type
2 (LQT2) subjects.
BACKGROUND Mutations in HERG (LQT2), the gene encoding the rapid delayed rectifier K current IKr,
account for a significant proportion of congenital long QT syndrome (LQTS). The
magnitude of IKr is paradoxically increased by an increase in extracellular K
. We tested the
hypothesis that long-term oral potassium supplementation results in a mild, sustainable
increase in serum K that improves repolarization abnormalities in subjects with LQT2.
METHODS After an initial evaluation consisting of electrocardiography, electrolytes, blood urea nitrogen,
and creatinine, escalating doses of potassium chloride (KCl) and spironolactone were
administered to eight subjects with six distinct HERG mutations. Medications were
continued for four weeks, at which time, the final evaluation was undertaken. Beta-adrenergic
blocking therapy was maintained.
RESULTS The subjects ranged in age from 11 to 52 years. The average daily KCl and spironolactone
dose was 3.3  1.5 mEq/kg and 3.5  1.2 mg/kg, respectively, and this regimen resulted in
an increase in serum K from 4.0  0.3 to 5.2  0.3 mEq/l. There were no serious
complications associated with therapy. The increase in serum K resulted in a decrease in the
corrected QT interval from 526  94 to 423  36 ms (mean  SD; lead V2). Both QT
dispersion and T-wave morphology improved in most subjects.
CONCLUSIONS Long-term oral potassium administration increases serum K in patients with LQT2. This
can be achieved safely and results in improvement in repolarization. Further studies are
warranted to determine whether this will reduce the incidence of life-threatening events in
LQTS patients. (J Am Coll Cardiol 2003;42:1777–82) © 2003 by the American College
of Cardiology Foundation
Congenital long QT syndrome (LQTS) is an inherited
disorder of myocellular repolarization characterized by elec-
trocardiographic (ECG) abnormalities, syncope, and sud-
den death (1). Mortality may approach 50% in untreated,
symptomatic individuals (2). Although beta-adrenergic
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blocking drugs are the mainstay of therapy, their use has
only been validated by observational and retrospective stud-
ies (3,4). Other therapies for LQTS include permanent
pacing, left cardiac sympathetic denervation, and defibrilla-
tor implantation (1). None of these therapies addresses the
fundamental differences in the molecular pathogenesis of
LQTS. Molecular genetic studies have revealed that LQTS
is a heterogeneous disorder caused by mutations in several
cardiac ion channel genes (5). Mutations in HERG (LQTS
type 2, or LQT2) account for 45% of the LQTS mutations
identified to date (6). HERG encodes the channel that
underlies the cardiac rapidly activating delayed rectifier K
current, IKr (7,8). Modulation by extracellular potassium is
a hallmark of IKr in myocytes and heterologously expressed
HERG channels (7,9). Outward current is paradoxically
increased, despite a decrease in the electrochemical gradient,
by increasing extracellular K within the physiologic range.
With this in mind, we hypothesized that impaired IKr
channel function could be improved by exogenously admin-
istered potassium, resulting in increased outward K current
and shortening of repolarization. Indeed, an early increase
in serum K by intravenous potassium chloride (KCl) and
oral spironolactone resulted in a reduction in the resting
corrected QT interval (QTc) and normalization of QT
dispersion and the QT/RR slope in subjects with HERG
mutations (10).
The aim of this study was to determine the safety,
feasibility, and efficacy of long-term oral potassium supple-
mentation in LQT2 subjects. Therapy with KCl and spi-
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ronolactone resulted in a sustained, mild increase in serum
K from 4.0  0.3 to 5.2  0.3 mEq/l, with no adverse
events. The increase in serum K was associated with a
decrease in QTc from 526  94 to 423  36 ms (lead V2).
QT dispersion also improved in all eight subjects. This
study underscores the potential benefit of potassium sup-
plementation as a novel treatment strategy for LQTS. Our
findings serve as the basis for a larger study powered to
determine the effect of this therapy on the improvement in
cardiac event rates.
METHODS
The study was reviewed and approved by the University of
Utah’s Institutional Review Board. Written, informed con-
sent was obtained. We prospectively studied eight patients
from six families with HERG mutations. No subject had
structural heart disease. No changes were made in the study
participant’s prior therapy while taking part in this protocol.
Six subjects, including four children, were taking beta-
blockers. One adult had a permanent atrial pacemaker in
place due to intolerance of beta-blockers. A 52-year-old
asymptomatic patient was not receiving therapy.
Baseline testing included an ECG, 24-h Holter monitor,
exercise treadmill study (standard Bruce protocol), serum
pregnancy test, serum electrolytes, blood urea nitrogen, and
creatinine. After the baseline evaluation was completed, oral
KCl and spironolactone therapy was initiated. The starting
dose of KCl was 1.5 mEq/kg (maximum starting dose 20
mEq) every 12 h and spironolactone 1.5 mg/kg (maximum
100 mg) every 12 h. The KCl dose was increased by
0.5-mEq/kg increments alternating with 0.5-mg/kg in-
creases in the dose of spironolactone every 48 to 72 h. The
target serum K level was 1.5 mEq/l above baseline. Serum
electrolytes, blood urea nitrogen, and creatinine levels were
obtained every 48 to 72 h and before increases in the
medication dose. Once the target serum K level was
reached and maintained at steady-state for three consecutive
determinations over a six- to nine-day period, the frequency
of blood testing was decreased to weekly for the four-week
maintenance period. At the conclusion of the four-week
maintenance phase of the study, the blood tests and ECG
were repeated.
The ECGs were analyzed manually in a blinded fashion.
The QT interval was defined as the intersection of a tangent
to the steepest down-slope of the dominant repolarization
wave with the isoelectric baseline. The T waves were rated
as biphasic when two distinct components of opposite
polarity were present. The T-wave morphology was rated as
notched when a second positive deflection interrupted the
descending phase of the T wave. QT dispersion was defined
as the difference between the longest and shortest QT
interval (11) and was measured in a minimum of eight ECG
leads.
Statistical analysis was performed using the Student
two-tailed t test (SigmaStat version 2.03, SPSS Inc., Chi-
cago, Illinois) and a linear mixed model analysis (S-Plus
version 6.0, Insightful, Seattle, Washington). A p value
0.05 was required for statistical significance. Data are
presented as the mean  SD.
RESULTS
Table 1 describes the HERG nucleotide substitution, coding
effect, and functional effect of the mutation in the eight
subjects. Figure 1 depicts the location of the mutations
Abbreviations and Acronyms
HERG  human ether-a-go-go related gene
IKr  rapidly activating delayed rectifier K
 current
LQTS  long QT syndrome
LQT2  long QT syndrome type 2
QTc  corrected QT interval
Table 1. Location and Functional Effects of HERG Mutations in Eight Study Patients
Patient No.
Nucleotide
Change Coding Effect Location Functional Effect Reference
1 G1714T G572C S5 Unknown
2 A1408G N470D S2 Trafficking defect 20
3 G2044T E682X C-terminus Unknown
4 G1681A A561T S5 Trafficking defect* 21,22*
5 C1841T A614V Pore helix Dominant-negative effect,
altered inactivation
23
6 G1681A A561T S5 Trafficking defect* 21,22*
7 C3040T R1014X C-terminus Trafficking defect 24
8 C3040T R1014X C-terminus Trafficking defect 24
*Trafficking defect described for a Val substitution at the same position (A561V). Subjects 4 and 6 are related family members,
as are Subjects 7 and 8.
Figure 1. Topology of the HERG channel subunit and location of HERG
mutations. Six membrane-spanning domains are depicted, with the pore
helix located between the fifth and sixth transmembrane domains.
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within the HERG channel subunit. Functional character-
ization has been reported for six of eight mutations, with the
majority of mutations causing dominant-negative effects by
altering protein processing and trafficking. Demographic
data, medication and genetic information, and serum K
levels are detailed in Table 2. The average doses of KCl and
spironolactone required to attain the target serum K were
3.3  1.5 mEq/kg and 3.5  1.2 mg/kg, respectively,
resulting in a mean increase in serum K of 1.2 mEq/l.
Serum K values 6 mEq/l occurred on three occasions in
three patients, with the maximum measured level of 6.2
mEq/l. No complications were described. Overall, the
therapy was well tolerated without significant side effects.
One subject complained of mild muscle cramps, and an-
other experienced orthostatic dizziness that improved with
increased fluid intake. Renal function measurements re-
mained stable throughout the trial.
An increase in serum K resulted in a decrease in the
resting QTc in all subjects (Fig. 2). The three subjects with
the longest QTc experienced the greatest reduction in QTc
(Patient 2: 684 to 496 ms; Patient 5: 638 to 441 ms; and
Patient 7, 560 to 408 ms in QTc lead V2 before and after
therapy). There was no apparent correlation between the
location of the mutation and the effect of QTc shortening
(Table 1, Fig. 2). The mean QTc, as measured in leads II,
V2, and V4, was significantly reduced after therapy with KCl
and spironolactone (Fig. 3). For 81 ECG recordings and
serum K determinations, the QTc correlated inversely
with serum K (r  0.52, p  0.0001 by linear mixed
model analysis) (Fig. 4). To assess QTc variability within
the study population, we analyzed all available ECGs
obtained before therapy. Although there was some variabil-
ity in the measured QTc, the degree of variability was less
than the decrease in QTc noted at the completion of
therapy (Table 3).
QT dispersion also significantly improved in the study
patients. The QT dispersion at baseline was 100  54 ms
and decreased to 41  16 ms at the end of the study period
(p  0.03). Mutations in HERG are associated with a
distinctive T-wave morphology (12). The ECGs of all eight
study patients demonstrated the typical bifid or notched
appearance of the T-wave. An elevation in serum K
resulted in normalization of the abnormal T-wave morphol-
ogy in four of eight subjects (Fig. 5).
DISCUSSION
The application of molecular genetics to cardiovascular
disease has allowed the identification of mutations in ion
channel genes as the cause of LQTS. The specific genotype
influences the characteristics of the clinical phenotype,
including the arrhythmia trigger, frequency of life-
threatening events, and T-wave morphology (12–14). The
discovery of a distinct molecular basis for LQTS has
fostered a hope for specific therapy directed at the gene
defect. Ta
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The rationale for the current study is based on the
observation that the IKr magnitude increases paradoxically
with increased extracellular K, that is, despite a decrease in
the chemical driving force. We hypothesized that increasing
serum K within the physiologic range would augment the
repolarizing current and result in improvements in repolar-
ization parameters in individuals with HERG mutations.
We previously reported that an early increase in serum K
achieved by intravenous KCl reduced the QTc interval by
24% and improved repolarization parameters in LQT2
subjects (10). The current study demonstrates that a sus-
tainable, mild increase in serum K can be safely main-
tained by oral potassium supplementation and spironolac-
tone. The increase in serum K was associated with a
significant reduction in QTc and QT dispersion in all
subjects, as well as normalization of the T-wave morphology
in one-half of the subjects. A dramatic decrease in QTc with
elevated serum K was observed in three individuals. The
improvement in repolarization parameters achieved in this
study suggests that oral KCl and spironolactone may be
effective adjunctive therapy, together with beta-blockers, for
the treatment of LQTS.
The precise mechanism whereby an increase in serum K
results in shortening of the QT interval in study patients is
not known. The primary mechanism of HERG channel
sensitivity to extracellular K is relief of the channel block
by extracellular Na (15,16). Additionally, increased extra-
cellular K induces a depolarizing shift in the voltage
Figure 2. The individual response of the corrected QT interval (QTc) to
increased serum K in long QT syndrome type 2 (LQT2) subjects. Scatter
plot of QTc intervals measured in lead V2 at baseline and after a four-week
course of oral KCl and spironolactone. An increase in serum K from 4.0
 0.3 at baseline to 5.2  0.3 mEq/l resulted in a decrease in QTc in all
subjects.
Figure 3. The mean corrected QT interval (QTc) shortens in response to an elevation in serum K. Graphic demonstration of the mean QTc intervals
measured in ECG leads II, V2, and V4 at baseline and after increasing the serum K
 level with oral KCl and spironolactone. The treatment protocol was
associated with a statistically significant decrease in QTc (p value  0.002, 0.003, and 0.003 for leads II, V2, and V4, respectively, using the paired t test).
Figure 4. Relationship between individual serum K measurement and
corrected QT interval (QTc). Scatter plot demonstrating a negative correlation
between the QTc interval and serum K level from eight study patients (total
of 81 determinations). Individual symbols represent a single study patient (Fig.
2). (r  0.52, p  0.0001 by linear mixed model analysis). The ECGs and
serum electrolytes were obtained on the same day.
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dependence of HERG channel inactivation, resulting in an
increase in channel availability (17,18). Either of these two
mechanisms might increase the current magnitude through
homomultimeric wild-type HERG channels or heteromul-
timeric channels formed by wild-type and mutant subunits.
The observation that HERG-specific T-wave dysmor-
phisms were normalized in some subjects suggests that IKr
was specifically increased. Alternatively, the increase in the
repolarizing current may be due to an increased magnitude
of the inward rectifier K current, IK1, which is also
paradoxically sensitive to increased extracellular K (19).
This hypothesis is more appealing given that the majority of
the mutations cause a dominant-negative effect (Table 1)
Figure 5. The effect of elevated serum K on T-wave morphology. Representative ECG tracings from study Patients 2, 4, 5, and 6, showing the
improvements in repolarization and T-wave morphology after increasing serum K. Values represent serum K levels at baseline and after four weeks of
KCl and spironolactone therapy.
Table 3. Corrected QT Interval Variability (Lead V2) on
Pre-Treatment Electrocardiograms
Patient
No. n*
Mean QTc
(ms) SD
CI of
Mean
QTc With KCl
Therapy (ms)
1 2 521 1.4 12.7 74
2 3 655 25.4 63.1 188
3 3 455 12.7 31.5 52
4 4 451 9.3 14.8 40
5 4 602 25.4 40.3 197
6 5 506 39.1 48.6 53
7 4 538 17.1 27.2 152
8 3 453 4.2 10.3 68
*Number of ECGs available before enrollment.
CI  95% confidence interval; QTc  change in corrected QT interval; SD 
standard deviation.
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(20–24). It is unlikely that the improvement in repolariza-
tion parameters was due to a direct effect of spironolactone,
given that spironolactone derivatives prolong the action
potential duration in isolated cardiac preparations (25).
However, we cannot exclude an indirect effect of aldoste-
rone blockade on myocellular repolarization. Finally, in-
creased serum potassium may exert secondary effects on
other ion channels critical in modulating the cardiac action
potential duration by altering the resting membrane poten-
tial of cardiomyocytes.
Study limitations. This is a small series with a relatively
short-term duration of therapy and follow-up. Although the
QTc was significantly shortened by treatment with oral
potassium supplementation, it remains to be proven that
changes in the QTc duration will translate into a decreased
risk of symptoms or sudden cardiac death. It is also unclear
whether the observed increase in serum K is sustainable
over the long run, without significant side effects. Although
the side effects of therapy were minimal, the long-term
safety and efficacy of oral KCl and spironolactone remain to
be determined. Gynecomastia, a well-characterized side
effect of high-dose spironolactone therapy, was not seen in
our subjects, but may emerge as an important complication
with prolonged therapy.
The results of the study must also be interpreted with
caution, given the small sample size. Larger studies of
greater duration are currently in progress to address the
question of a long-term benefit of KCl therapy in LQTS.
Clinical implications. Irrespective of the specific current
that is modulated by extracellular K, an increase in serum K
would be predicted to shorten repolarization in other forms of
inherited LQTS. In fact, one could argue that the effect of
increased serum K may be greater in KCNQ1 and SCN5A
subjects due to the presence of fully functional HERG chan-
nels. In contrast, mexiletine is effective in shortening the QT
interval only in individuals with mutations in SCN5A (LQT3),
presumably by blocking the abnormally sustained plateau Na
current (26). Whether increasing serum K proves to be
effective in improving repolarization parameters in other forms
of LQTS is currently under investigation.
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